Active, not recruitingPhase 2NCT04925024

Evaluation of Lomecel-B™ Injection in Patients With Hypoplastic Left Heart Syndrome (HLHS): A Phase IIb Clinical Trial.

Studying Hypoplastic left heart syndrome

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Longeveron Inc.
Principal Investigator: Stu Berger, MD
Ann & Robert H Lurie Children's Hospital of Chicago
Intervention: Lomecel-B medicinal signaling cells(biological)
Enrollment: 40 target
Eligibility: All sexes
Timeline: 2021 – 2026

Study locations (10)

Children's Hospital of Los Angeles, Los Angeles, California, United States
Children's Hospital Colorado, Aurora, Colorado, United States
Children's Healthcare of Atlanta, Atlanta, Georgia, United States
Advocate Children's Hospital, Chicago, Illinois, United States
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
Boston Children's Hospital, Boston, Massachusetts, United States
Children's Nebraska, Omaha, Nebraska, United States
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Primary Children's Hospital/University of Utah, Salt Lake City, Utah, United States

Collaborators

National Heart, Lung, and Blood Institute (NHLBI) · Ann & Robert H Lurie Children's Hospital of Chicago · The University of Texas Health Science Center, Houston

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04925024 on ClinicalTrials.gov

Other trials for Hypoplastic left heart syndrome

Additional recruiting or active studies for the same condition.

See all trials for Hypoplastic left heart syndrome →

← Back to all trials